Obesity Drugs at BMI 27 or 30: What Labels and Trials Say

HealthRX.com

At BMI 27, labels require a weight-related condition

Print or save as PDF

Key numbers

  • 6.5%Primary cardiovascular event rate on semaglutide in SELECT adults aged 45 or older with cardiovascular disease and a BMI of 27 or higherSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
  • 8.0%Primary cardiovascular event rate on placebo in the same SELECT group of adults aged 45 or older with cardiovascular diseaseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
  • BMI of 35Bariatric surgery threshold: recommended above this BMI regardless of comorbidity, per ASMBS/IFSO guidanceSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026

At a glance

  • BMI 27 to under 30 / Overweight: Wegovy and Zepbound labels require at least one weight-related condition [1][2][5]
  • BMI 30 or higher / Obesity alone meets the label criterion [5][1][2]
  • WHO / GLP-1 therapy conditionally recommended for adults with obesity (BMI 30 or higher), not at BMI 27 [6][13]
  • Surgery / ASMBS/IFSO 2022: recommended above BMI 35 regardless of comorbidity; considered at BMI 30 to 34.9 with metabolic disease [7]

What the labels say about BMI 27

Wegovy and Zepbound are labeled for weight reduction in adults with obesity, or in adults with overweight who have at least one weight-related condition [1][2]. The labels use the terms obesity and overweight rather than printing a BMI number. Under adult BMI categories, overweight is a BMI of 25 to under 30 and obesity starts at 30 [5]. The 27 and 30 figures come from the trials: STEP 1 enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related coexisting condition [3], and SURMOUNT-1 used the same entry rule [4].

Older options print the numbers. Xenical (orlistat) is labeled for people with a BMI of 30 or higher, or 27 or higher with other risk factors [8]. Phentermine and phendimetrazine use the same split, 30 or higher, or 27 or higher with risk factors [9][10], while benzphetamine and diethylpropion are labeled at a BMI of 30 or higher [11][12]. Those four appetite suppressants are labeled for short-term use only, described as a few weeks [9][11][10][12].

WHO's safety committee warns about GLP-1 use without an indication below a BMI of 30, alongside unregulated and falsified products [13].

What people on Reddit report

Reddit accounts reacting to a recent Zepbound label change that removed BMI ranges, plus a discussion of whether the overweight range is a meaningful cutoff for treatment.

C0nnecti0n3 · Zepbound

Don't be fooled - it won't change anything about insurance coverage. They make their own rules and only defer to the FDA label if it is to their advantage.

Reader expects the removal of BMI ranges from the label to leave insurance coverage rules unchanged.

Read the source discussion

catplusplusok · Zepbound

I am concerned that too much dismissal will cause people to convince themselves they are fine despite what the scale says.

Reader values BMI as a quick screening tool and worries that dropping it from labels could lead people to ignore weight problems.

Read the source discussion

RunningFNP · Zepbound

I appreciate them doing this but it's also funny to me who's in trial for retatrutide and they've been using BMI the whole time.

Trial participant notes that the drug maker still uses BMI in its own trial design despite the label change.

Read the source discussion

Jquemini · medicine

Why is it important to get someone with a BMI of 27 to a BMI of 23? Except maybe in the Asian population, I don't think there is great evidence this will reduce risk of chronic diseases or improve mortality.

Clinician questions whether moving a patient from overweight into the normal BMI range gives a real health benefit.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Dr Holly Lofton on choosing a GLP-1 drug and staying on label

Dr Lofton argues that the first step in choosing a GLP-1 drug is confirming the right condition. She says a patient with type 2 diabetes should generally get the version indicated for diabetes, while a patient with obesity alone should get the chronic weight management version. She stresses staying on label because it keeps patients able to access the right medication and matches the populations studied in clinical trials, and she calls use in other populations off label. She also describes the recent Wegovy indication for reduced cardiac risk in people with a higher BMI and prior heart history, which she says has changed access to the drug.

Who is speaking?

Dr Holly Lofton. Obesity specialist, as described on the Medscape channel and in the video description Background

Episode notes and full video

Wegovy's cardiovascular indication

Wegovy also has an indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. Both parts are required: overweight by itself is not enough, and established cardiovascular disease is the qualifying condition.

In SELECT, 17,604 adults aged 45 or older with cardiovascular disease and a BMI of 27 or higher, without diabetes, had a primary cardiovascular event in 6.5% on semaglutide versus 8.0% on placebo (HR 0.80) [14].

How other thresholds compare

  • CDC and WHO: a BMI of 30 or higher is obesity and 25 to under 30 is overweight; CDC calls BMI a screening measure to be considered with other factors [5][15].
  • Lancet Diabetes and Endocrinology Commission, 2025: 58 experts separate clinical obesity from preclinical obesity. BMI should be a screening or population measure, not an individual measure of health. The Commission recommends confirming excess body fat with direct measurement or another measure such as waist circumference, waist-to-hip or waist-to-height ratio, except that it says excess fat can be assumed when BMI is above 40 [16].
  • WHO, December 2025: a conditional recommendation that GLP-1 therapies may be used for long-term treatment of adults with obesity (a BMI of 30 or higher per WHO), excluding pregnancy, alongside intensive behavioral interventions [6][13].
  • ASMBS/IFSO, 2022: surgery is recommended above a BMI of 35 regardless of comorbidity and should be considered at BMI 30 to 34.9 with metabolic disease [7].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the label, which adults are Wegovy and Zepbound labeled for weight reduction in?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Frequently asked questions

Does a BMI of 27 alone qualify for weight-loss medication?
Not for Wegovy or Zepbound. Their labels cover adults with obesity, or adults with overweight plus at least one weight-related condition [1][2]. Obesity starts at a BMI of 30, and 25 to under 30 is overweight [5]. The trials enrolled at BMI 30 or higher, or 27 or higher with a weight-related condition [3][4].
Does Wegovy have a separate cardiovascular indication at BMI 27?
The Wegovy label has an indication for reducing major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. Overweight alone is not enough. SELECT enrolled adults with cardiovascular disease and a BMI of 27 or higher, without diabetes [14].
Is the BMI threshold different for bariatric surgery?
Yes. ASMBS/IFSO 2022 recommends surgery at a BMI above 35 regardless of comorbidity and says it should be considered at 30 to 34.9 with metabolic disease [7].
What does WHO recommend for adults with obesity?
WHO's 2025 guideline conditionally recommends GLP-1 therapies for long-term treatment of adults with obesity, excluding pregnancy, alongside intensive behavioral interventions [6]. WHO identifies obesity in adults as a BMI of 30 or higher, and its safety committee warns against use without an indication below a BMI of 30 [13].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Which BMI indicates obesity?

A BMI of 30 or higher is obesity under CDC and WHO categories, and 25 to under 30 is overweight. CDC calls BMI a screening measure to be considered together with other factors.

What are some common weight loss medication pills?

The older options named are Xenical (orlistat), phentermine, phendimetrazine, benzphetamine, and diethylpropion. The four appetite suppressants are labeled for short-term use only, described as a few weeks. Benzphetamine and diethylpropion are labeled at a BMI of 30 or higher.

What are the new BMI guidelines?

A 2025 Lancet Diabetes and Endocrinology Commission says BMI should be a screening or population measure, not an individual measure of health. It recommends confirming excess body fat with direct measurement or another measure such as waist circumference, waist-to-hip, or waist-to-height ratio, except that excess fat can be assumed when BMI is above 40.

References

Show all 19 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
  2. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
  4. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
  5. Adult BMI Categories | BMI | CDC.
  6. WHO issues global guideline on the use of GLP-1 medicines in treating obesity.
  7. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3-14.
  8. U.S. National Library of Medicine, DailyMed. Xenical capsules (orlistat) prescribing information. Xenical capsules (orlistat) label
  9. U.S. National Library of Medicine, DailyMed. Phentermine hydrochloride tablets (Sun) prescribing information. Phentermine hydrochloride tablets (Sun) label
  10. U.S. National Library of Medicine, DailyMed. Phendimetrazine ER capsules (Acertis) (phendimetrazine tartrate) prescribing information. Phendimetrazine ER capsules (Acertis) (phendimetrazine tartrate) label
  11. U.S. National Library of Medicine, DailyMed. Benzphetamine tablets (KVK-Tech) (benzphetamine hydrochloride) prescribing information. Benzphetamine tablets (KVK-Tech) (benzphetamine hydrochloride) label
  12. U.S. National Library of Medicine, DailyMed. Diethylpropion tablets (KVK-Tech) (diethylpropion hydrochloride) prescribing information. Diethylpropion tablets (KVK-Tech) (diethylpropion hydrochloride) label
  13. Statement from the Joint Meeting of the Advisory Committee on Safety of Medicinal Products (ACSoMP) and the Global Advisory Committee on Vaccine Safety (GACVS) on the safe and appropriate use of GLP‑1 receptor agonists.
  14. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
  15. Obesity and overweight.
  16. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262.
  17. Reddit participants. Eli Lilly drops body mass ranges from label (r/Zepbound). Accessed 2026-11-10.
  18. Reddit participants. Discrepancy in "ideal weight" and weight we treat to (r/medicine). Accessed 2026-11-10.
  19. Medscape. GLP-1 Receptor Agonists: Which Drug for Which Patient?. Accessed 2026-11-10.
Evidence overview for Obesity Drugs at BMI 27 or 30: What Labels and Trials Say